CEL-SCI CORPORATION Stock Issued During Period, Value, Issued for Services
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- CEL-SCI CORPORATION stock issued during period, value, issued for services for the quarter ending 2026-06-30 was $156.02K, a 22.70% increase year-over-year.
- CEL-SCI CORPORATION stock issued during period, value, issued for services for the quarter ending 2026-03-31 was $56.94K, a 5.42% decline year-over-year.
- CEL-SCI CORPORATION stock issued during period, value, issued for services for the quarter ending 2025-12-31 was $57.73K, a 85.42% decline year-over-year.
- CEL-SCI CORPORATION stock issued during period, value, issued for services for the quarter ending 2025-06-30 was $127.16K, a 18.31% decline year-over-year.
- CEL-SCI CORPORATION stock issued during period, value, issued for services for fiscal 2025 was $750.33K, a 1.26% decline from fiscal 2024.
- CEL-SCI CORPORATION stock issued during period, value, issued for services for fiscal 2024 was $759.90K, a 34.26% increase from fiscal 2023.
- CEL-SCI CORPORATION stock issued during period, value, issued for services for fiscal 2023 was $565.98K, a 18.39% decline from fiscal 2022.
- CEL-SCI CORPORATION stock issued during period, value, issued for services for fiscal 2022 was $693.49K, a 42.00% decline from fiscal 2021.
| Period end | Stock Issued During Period, Value, Issued for Services 3 month | Stock Issued During Period, Value, Issued for Services 12 month |
|---|---|---|
| 2026-06-30 | $156.02K 10-Q · filed 2026-08-14 | |
| 2026-03-31 | $56.94K 10-Q · filed 2026-08-14 | |
| 2025-12-31 | $57.73K 10-Q · filed 2026-08-14 | |
| 2025-09-30 | $750.33K 10-K · filed 2025-12-29 | |
| 2025-06-30 | $127.16K 10-Q · filed 2026-08-14 | |
| 2025-03-31 | $60.20K 10-Q · filed 2026-08-14 | |
| 2024-12-31 | $396.09K 10-Q · filed 2026-08-14 | |
| 2024-09-30 | $759.90K 10-K · filed 2025-12-29 | |
| 2024-06-30 | $155.66K 10-Q · filed 2025-08-14 | |
| 2024-03-31 | $380.87K 10-Q · filed 2025-08-14 | |
| 2023-12-31 | $202.31K 10-Q · filed 2025-08-14 | |
| 2023-09-30 | $565.98K 10-K · filed 2025-01-13 | |
| 2023-06-30 | $135.67K 10-Q · filed 2024-08-14 | |
| 2023-03-31 | $100.64K 10-Q · filed 2024-08-14 | |
| 2022-12-31 | $91.62K 10-Q · filed 2024-08-14 | |
| 2022-09-30 | $693.49K 10-K · filed 2023-12-21 | |
| 2022-06-30 | $122.27K 10-Q · filed 2022-08-12 | |
| 2022-03-31 | $140.05K 10-Q · filed 2023-05-12 | |
| 2021-12-31 | $143.16K 10-Q · filed 2022-08-12 | |
| 2021-09-30 | $1.20M 10-K · filed 2022-12-27 | |
| 2021-06-30 | $267.07K 10-Q · filed 2022-08-12 | |
| 2021-03-31 | $379.28K 10-Q · filed 2022-08-12 | |
| 2020-12-31 | $152.45K 10-Q · filed 2022-08-12 | |
| 2020-09-30 | $972.67K 10-K · filed 2021-12-21 | |
| 2020-06-30 | $205.38K 10-Q/A · filed 2020-12-31 | |
| 2020-03-31 | $235.02K 10-Q · filed 2021-05-17 | |
| 2019-12-31 | $84.45K 10-Q · filed 2021-05-17 | |
| 2019-09-30 | $878.59K 10-K · filed 2020-12-29 | |
| 2019-06-30 | $140.27K 10-Q/A · filed 2020-12-31 | $912.47K derived: sum of 4 quarters · filed 2020-12-31 |
| 2019-03-31 | $225.63K 10-Q/A · filed 2020-12-31 | $981.40K derived: sum of 4 quarters · filed 2020-12-31 |
| 2018-12-31 | $202.38K 10-Q/A · filed 2020-12-31 | $984.27K derived: sum of 4 quarters · filed 2020-12-31 |
| 2018-09-30 | $344.19K derived: 10-K/A 12 month − 10-Q 9 month · filed 2019-12-23 | $693.19K 10-K/A · filed 2019-12-23 |
| 2018-06-30 | $209.20K 10-Q · filed 2019-08-14 | $515.69K derived: sum of 4 quarters · filed 2019-08-14 |
| 2018-03-31 | $228.50K 10-Q · filed 2019-08-14 | $345.49K derived: sum of 4 quarters · filed 2019-08-14 |
| 2017-12-31 | $25.41K 10-Q · filed 2019-08-14 | $150.99K derived: sum of 4 quarters · filed 2019-08-14 |
| 2017-09-30 | $52.58K derived: 10-K 12 month − 10-Q 9 month · filed 2018-12-19 | $204.58K 10-K · filed 2018-12-19 |
| 2017-06-30 | $39.00K 10-Q · filed 2018-08-14 | |
| 2017-03-31 | $34.00K 10-Q · filed 2018-05-15 | |
| 2016-09-30 | $690.31K 10-K · filed 2017-12-29 | |
| 2015-09-30 | $533.98K 10-K/A · filed 2017-12-11 | |
| 2014-09-30 | $627.12K 10-K/A · filed 2017-12-11 | |
| 2013-09-30 | $360.93K 10-K · filed 2015-12-11 | |
| 2012-09-30 | $558.29K 10-K · filed 2014-12-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Quince Therapeutics, Inc. (QNCX) | United States | $0.031B | |
| aTYR PHARMA INC (ATYR) | United States | $0.033B | -0.98 |
| Estrella Immunopharma, Inc. (ESLA) | United States | $0.020B | |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| Scilex Holding Co (SCLX) | United States | $0.042B | -0.14 |
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |